Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review

Radiotherapy and Oncology

Volumn 64, Issue 3, 2002, Pages 259-273

  Laperriere, Normand ^a   Zuraw, Lisa ^b   Cairncross, Gregory ^c  

^a University of Toronto   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Malignant glioma; Practice guideline; Radiotherapy; Systematic review

Indexed keywords

BRAIN RADIATION; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; GLIOBLASTOMA; HUMAN; MORBIDITY; PERFORMANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; REVIEW; SURVIVAL RATE;

ADULT; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; GLIOMA; HUMANS; RADIOSURGERY; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 0036711451     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(02)00078-6     Document Type: Review

References (81)

1. Andersen A.P. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol. 17:1978;475-484.
2. Bauman G.S., Gaspar L.E., Fisher B.J., et al. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 29:1994;835-839.
3. Bleehen N.M., Wiltshire C.R., Plowman P.N., et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma. Br J Cancer. 43:1981;436-442.
4. Bleehen N.M., Stenning S.P. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer. 64:1991;769-774.
5. Brada M., Sharpe G., Rajan B., et al. Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. Int J Radiat Oncol Biol Phys. 43:1999;287-292.
6. Buatti J.M., Friedman W.A., Bova F.J., et al. Linac radiosurgery for high-grade gliomas: the University of Florida experience. Int J Radiat Oncol Biol Phys. 32:1995;205-210.
7. Cardinale R.M., Schmidt-Ullrich R.K., Benedict S.H., et al. Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation. Radiat Oncol Invest. 6:1998;175-181.
8. Chang C.H., Horton J., Schoenfeld D., et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multdisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 52:1983;997-1007.
9. Constine L.S., Konski A., Ekholm S., et al. Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys. 15:1988;319-330.
10. Corn W.C., Yousem D.M., Scott C.B., et al. White matter changes are correlated significantly with radiation dose. Cancer. 74:1994;2828-2835.
11. Curran W.J., Hecht-Levitt C., Schut L., et al. Magnetic resonance imaging of cranial radiation lesions. Int J Radiat Oncol Biol Phys. 13:1987;1093-1098.
12. Curran W.J. Jr, Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 85:1993;704-710.
13. Curran W.J. Jr, Scott C.B., Weinstein A.S., et al. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol. 11:(5):1993;857-862.
14. DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 7:1986;177-188.
15. Deutsch M., Green S.B., Strike T.A., et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys. 16:1989;1389-1396.
16. Duncan W., McLelland J., Jack W.J., et al. Report of a randomised pilot study of the treatment of patients with supratentorial gliomas using neutron irradiation. Br J Radiol. 59:1986;373-377.
17. Duncan W., McLelland J., Jack W.J., et al. The results of a randomised trial of mixed-schedule (neutron/photon) irradiation in the treatment of supratentorial Grade III and Grade IV astrocytoma. Br J Radiol. 59:1986;379-383.
18. EORTC Brain Tumour Group . Misonidazole in radiotherapy of supratentorial malignant brain gliomas in adult patients: a randomized double-blind study. Eur J Cancer Clin Oncol. 19:1983;39-42.
19. Ford J.M., Stenning S.P., Boote D.J., et al. A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol (R Coll Radiol). 9:1997;20-24.
20. Fulton D.S., Urtasun R.C., Shin K.H., et al. Misonidazole combined with hyperfractionation in the management of malignant glioma. Int J Radiat Oncol Biol Phys. 10:1984;1709-1712.
21. Gannett D., Stea B., Lulu B., et al. Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas. Int J Radiat Oncol Biol Phys. 33:1995;461-468.
22. Glinski B. Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial. J Neurooncol. 16:1993;167-172.
23. Green S.B., Shapiro W.R., Burger P.C., et al. A randomized trial of interstitial radiotherapy (RT) boost for newly diagnosed malignant glioma: Brain Tumor Cooperative Group (BTCG) trial 8701 (abstract). Proc Annu Meet Am Soc Clin Oncol. 13:1994;174.
24. Griffin T.W., Davis R., Laramore G., et al. Fast neutron radiation therapy for glioblastoma multiforme. Results of an RTOG study. Am J Clin Oncol. 6:1983;661-667.
25. Hall E.J. Radiobiology for the Radiologist. 1988;293-330 Lippincott, New York.
26. Hatlevoll R., Lindegaard K., Hagen S., et al. Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 56:1985;41-47.
27. Hochberg F.H., Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 30:1980;907-911.
28. Hoegler D.B., Davey P. A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neurooncol. 33:1997;201-204.
29. Horiot J.C., van den Bogaert W., Ang K.K., et al. European Organization for Research on Treatment of Cancer Trials using radiotherapy with multiple fractions per day. Front Radiat Ther Oncol. 22:1988;149-161.
30. Huncharek M. Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. Anticancer Res. 18:1998;1935-1939.
31. Kayama T., Yoshimoto T., Fujimoto S., et al. Intratumoral oxygen pressure in malignant brain tumor. J Neurosurg. 74:1991;55-59.
32. Keim H., Potthoff P.C., Schmidt K., et al. Survival and quality of life after continuous accelerated radiotherapy of glioblastoma. Radiother Oncol. 9:1987;21-26.
33. Kita M., Okawa T., Tanaka M., et al. Radiotherapy of malignant glioma-prospective randomized clinical study of whole brain vs. local irradiation [in Japanese]. Gan No Rinsho. 35:1989;1289-1294.
34. Kleinberg L., Slick T., Enger C., et al. Short course radiotherapy is an appropriate option for most malignant glioma patients. Int J Radiat Oncol Biol Phys. 38:1997;31-36.
35. Kondziolka D., Flickinger J.C., Bissonette D.J., et al. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery. 41:1997;776-783.
36. Kristiansen K., Hagen S., Kollevold T., et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 47:1981;649-652.
37. Laperriere N.J., Leung P.M., McKenzie S., et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys. 41:1998;1005-1011.
38. Laramore G.E., Diener-West M., Griffin T.W., et al. Randomized neutron dose searching study for malignant gliomas of the brain: results of an RTOG study. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 14:1988;1093-1102.
39. Laramore G.E., Martz K.L., Nelson J.S., et al. Radiation Therapy Oncology Group (RTOG) survival data on anaplastic astrocytomas of the brain: does a more aggressive form of treatment adversely impact survival? Int J Radiat Oncol Biol Phys. 17:1989;1351-1356.
40. Larson D.A., Gutin P.H., McDermott M., et al. Gamma knife for glioma: selection factors and survival. Int J Radiat Oncol Biol Phys. 36:1996;1045-1053.
41. Leibel S.A., Sheline G.E. Radiation therapy for neoplasms of the brain. J Neurosurg. 66:1987;1-22.
42. Loeffler J.S., Shrieve D.C., Alexander E. 3rd. Radiosurgery for glioblastoma multiforme: the importance of selection criteria. Int J Radiat Oncol Biol Phys. 30:1994;731-733.
43. Ludgate C.M., Douglas B.G., Dixon P.F., et al. Superfractionated radiotherapy in grade III, IV intracranial gliomas. Int J Radiat Oncol Biol Phys. 15:1988;1091-1095.
44. Masciopinto J.E., Levin A.B., Mehta M.P., et al. Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg. 82:1995;530-535.
45. Mehta M.P., Masciopinto J., Rozental J., et al. Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys. 30:1994;541-549.
46. MRC Working Party on Misonidazole in Gliomas . A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of grades 3 and 4 astrocytomas. Br J Radiol. 56:1983;673-682.
47. Nelson D.F., Curran W.J. Jr, Scott C., et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma - possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys. 25:1993;193-207.
48. Nelson D.F., Diener-West M., Horton J., et al. Combined modality approach to treatment of malignant gliomas-re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr. 6:1988;279-284.
49. Nelson D.F., Diener-West M., Weinstein A.S., et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys. 12:1986;1793-1800.
50. Nelson D.F., Nelson J.S., Davis D.R., et al. Survival and prognosis of patients with astrocytoma with atypical or anaplastic features. J Neuro-Oncol. 3:1985;99-103.
51. Okkan S., Uzel R., Ober A., et al. A randomized study of ornizadole as a radiosensitizer in high-grade astrocytomas: preliminary report. Radiosensitiz Newslett. 7:1988;1-3.
52. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 6:1994;509-518.
53. Paszat L., Laperriere N.J., Groome P.A., et al. A population-based study of the treatment and outcome of glioblastoma (abstract). Clin Invest Med. 22S:1999;S35.
54. Payne D.G., Simpson W.J., Keen C., et al. Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial. Cancer. 50:1982;2301-2306.
55. Phillips T.L., Prados M.D., Bodell W.J., et al. Rationale for and experience with clinical trials of halogenated pyrimidines in malignant gliomas: The UCSF/NCOG experience. Dewey W.C., Edington M., Fry R.J.M., et al. Radiation research: a twentieth-century perspective. 1992;601-606 Academic Press, San Diego, CA.
56. Pickles T., Goodman G.B., Rheaume D.E., et al. Pion radiation for high grade astrocytoma: results of a randomized study. Int J Radiat Oncol Biol Phys. 37:1997;491-497.
57. Prados M.D., Scott C., Sandler H., et al. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. Int J Radiat Oncol Biol Phys. 45:1999;1109-1115.
58. Rampling R., Cruickshank G., Lewis A.D., et al. Direct measurements of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys. 29:1994;427-431.
59. Sack H., Calcanis A., Godehardt E., et al. Postoperative radiotherapy of astrocytomas grade 3 and 4 with the radiosensitizer misonidazole. End results of a multicentric controlled German study [in German]. Strahlentherapie. 158:1982;466-469.
60. Sandberg-Wollheim M., Malmstrom P., Stromblad L.G., et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer. 68:1991;22-29.
61. Sarkaria J.N., Mehta M.P., Loeffler J.S., et al. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 32:1995;931-941.
62. Shapiro W.R., Dean F., Young D.F. Treatment of malignant glioma. A controlled study of chemotherapy and irradiation. Arch Neurol. 33:1976;494-500.
63. Shapiro W.R., Green S.B., Burger P.C., et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 71:1989;1-9.
64. Scott C.B., Curran W.J., Yung W.K.A. Long term results of RTOG 9006: A randomized study of hyperfractionated radiotherapy (RT) to 72.0 Gy & carmustine vs. standard RT & carmustine for malignant glioma patients with emphasis on anaplastic astrocytoma (AA) patients (abstract). Proc Annu Meet Am Soc Clin Oncol. 17:1998;401a.
65. Shenouda G., Souhami L., Podgorsak E.B., et al. Radiosurgery and accelerated radiotherapy for patients with glioblastoma. Can J Neurol Sci. 24:1997;110-115.
66. Shin K.H., Muller P.J., Geggie P.H. Superfractionation radiation therapy in the treatment of malignant astrocytoma. Cancer. 52:1983;2040-2043.
67. Shin K.H., Urtasun R.C., Fulton D., et al. Multiple daily fractionated radiation therapy and misonidazole in the management of malignant astrocytoma. A preliminary report. Cancer. 56:1985;758-760.
68. Shrieve D.C., Alexander E. 3rd, Black P.M., et al. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg. 90:1999;72-77.
69. Simpson W.J., Platts M.E. Fractionation study in the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1:1976;639-644.
70. Slotman B.J., Kralendonk J.H., van Alphen H.A., et al. Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors. Int J Radiat Oncol Biol Phys. 34:1996;895-898.
71. Sneed P.K., Stauffer P.R., McDermott M.W., et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 40:1998;287-295.
72. Stuschke M., Thames H.D. Hyperfractionated radiotherapy of human tumors: Overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys. 37:1997;259-267.
73. Stadler B., Karcher K.H., Kogelnik H.D., et al. Misonidazole and irradiation in the treatment of high-grade astrocytomas: further report of the Vienna Study Group. Int J Radiat Oncol Biol Phys. 10:1984;1713-1717.
74. Thomas R., James N., Guerrero D., et al. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother Oncol. 33:1994;113-116.
75. Urtasun R., Band P., Chapman J.D., et al. Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med. 294:1976;1364-1367.
76. Urtasun R., Feldstein M.L., Partington J., et al. Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial. Br J Cancer. 46:1982;101-108.
77. Valk P.E., Mathis C.A., Prados M.D., et al. Hypoxia in human gliomas: demonstration by PET with Fluorine-18-fluoromisonidazole. J Nucl Med. 33:1992;2133-2137.
78. Walker M.D., Alexander E. Jr, Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 49:1978;333-343.
79. Walker M.D., Green S.B., Byar D.P., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 303:1980;1323-1329.
80. Wallner K.E., Galicich J.H., Krol G., et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 16:1989;1405-1409.
81. Werner-Wasik M., Scott C.B., Nelson D.F., et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer. 77:1996;1535-1543.